Abstract
Article retracted . Рurpose. А meta-analysis of randomized clinical trials of efficiency and safety of retinalamin water-soluble polypeptide retinal fractions complex neuroprotective therapy in patients with dry age-related macular degeneration (amd), conducted in russia. Мethods. Published results of various clinical trials were searched by a single investigator using the “scientific electronic library” (elibrary.ru). meta-analysis included all clinical trials of retinalamin efficacy, where its route of administration and dosage corresponded with the guidelines for medical use of retinalamin in patients with dry amd. Results. Primary search revealed 320 publications concerning retinalamin. 11 of those presented results of randomized clinical trial that satisfied the requirements, and hence were included into the meta-analysis. beside the parabulbar and intramuscular administration, prescribed officially, retinalamin was also administered subconjunctivally, with electrophoresis and with subcutaneous injections in temporal zone. in three studies the observation period is 3 months, in one study it is 5 months, in four studies it is 6 months, and in two studies it is 12 months. in the rest of studies the observation period is less than 3 months. all the studies present the changes in visual acuity right after the therapy course. meta-analysis revealed a statistically significant visual acuity improvement, best discernible in patients with areds 3 amd stage up to 6 months after retinalamin treatment. the positive dynamics in visual acuity changing persists during the first 3 months. repeated therapy courses in 3–6 months provided further progress. perimetry revealed the increasing of visual field borders and decreasing of central scotomae amount and area; the findings have also improved after the repeated course. the electrophysiology studying showed the positive dynamics as well and correlated with visual acuity changes. optical coherence tomography, blood flow examination and a series of other tests were also used. however, varying diagnostic methods in different trials as well as a low level of statistical data processing, impeded the fulfillment of a comprehensive analysis. Conclusion. Randomized clinical trial meta-analysis proved the efficacy of retinalamin therapy in patients with dry amd
Highlights
Возрастная макулярная дегенерация (ВМД) — наиболее распространенное хроническое дегенеративное заболевание сетчатки, поражающее центральное зрение
The article published in the journal
промежуточной) стадии ВМД были получены сопоставимые результаты за некоторым преимуществом
Summary
Волжанина «Метаанализ рандомизированных клинических исследований эффективности нейропротекторной терапии сухой формы ВМД с использованием комплекса водорастворимых полипептидных фракций». 69–79) под названием «Метаанализ рандомизированных клинических исследований эффективности нейропротекторной терапии сухой формы ВМД с использованием комплекса водорастворимых полипептидных фракций», авторами которой являются В.П. The article of V.P. Erichev, S.Yu. Petrov, A.V. Volzhanin “Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis”, 2018, Volume 15, No 1 was returned from the press. The article published in the journal “Ophthalmology in Russia” (2018, Volume 15, No 1, Pp.69–79) titled “Efficiency of Retinoprotective Dry AMD. Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Metaanalysis”, the authors are V.P. Erichev, S.Yu. Petrov, A.V. Volzhanin, comments editor with the consent of the publisher. Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy:.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
